Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143845 · ClinicalTrials.gov registry record · Phase 2
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
A Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT00143845: Completed Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic, sponsored by University of Michigan Rogel Cancer Center.
NCT00143845 is a Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 54 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143845, a Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
Primary Outcome
The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows: Grade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI G
Conditions Studied
Interventions
- PROCEDURE Reduced intensity conditioning
- PROCEDURE Rapid immunosuppressive taper
- PROCEDURE Prophylactic donor leukocyte infusions
Study Locations (1)
Michigan
- The University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2003-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
What the finished NCT00143845 record still lists
NCT00143845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Reduced intensity conditioning is the first listed.
NCT00143845 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00143845 about?
NCT00143845 is a clinical study titled "Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant". The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
What is the current status of trial NCT00143845?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2003-04. Estimated completion is 2013-02.
What conditions does trial NCT00143845 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade.
What interventions are being tested in trial NCT00143845?
The interventions under investigation include: Reduced intensity conditioning (PROCEDURE), Rapid immunosuppressive taper (PROCEDURE), Prophylactic donor leukocyte infusions (PROCEDURE).
Who is sponsoring clinical trial NCT00143845?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143845 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00143845's enrollment target sits among peer trials
54 241st of 438 higher than 197 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia